

BRIAN SANDOVAL
Governor



RICHARD WHITLEY, MS
Director

MARTA JENSEN
Administrator

DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 East William Street, Suite 101
Carson City, Nevada 89701
Telephone (775) 684-3676 • Fax (775) 687-3893
<http://dhcfp.nv.gov>

NOTICE OF PUBLIC MEETING – PHARMACY AND THERAPEUTICS COMMITTEE

AGENDA

Date of Publication: August 28, 2018

Date and Time of Meeting: Thursday, September 27, 2018 at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP)

Place of Meeting: Springs Preserve
333 S. Valley View Blvd.
Las Vegas, Nevada 89107

Please check with staff to verify room location

There will not be a North Location for this meeting.

Webinar Registration: <https://optum.webex.com/optum/onstage/g.php?MTID=ef960c11cad07d87baa20f41da6a911dd>

OR

www.webex.com, select “Join,” enter Meeting Number 645 588 030, your name and email and then select, “Join.”

A Password should not be necessary, but if asked, enter “Medicaid1!”

OR

Audio Only: (763) 957-6300

Event Number: 645 588 030

Follow the instructions that appear on your screen to join the teleconference. Audio will also be broadcast over the internet (VoIP).

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Wendy Montgomery at: (775) 684-3722 or email wmontgomery@dncfp.nv.gov in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Items may be taken out of order.

Items may be combined for consideration by the public body.

Items may be pulled or removed from the agenda at any time.

Public comment is limited to five minutes per individual, organization or agency, but may be extended at the discretion of the Chairperson.

AGENDA

1. **Call to Order and Roll Call**
2. **Public Comment**
3. **Administrative**
 - a. **For Possible Action:** Review and Approve Meeting Minutes from June 28, 2018
 - b. Status Update by DHCFP
 1. Public Comment
4. **Proposed New Classes**
 - a. Respiratory Agents – Long-acting/maintenance therapy
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
 - b. Respiratory Agents – Short-acting/rescue

1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- 5. Annual Review – Established Drug Classes Being Reviewed Due to the Release of New Drugs**
- a. Antihistamines – H1 blockers – Non-Sedating H1 Blockers
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
 - b. Biologic Response Modifiers – Immunomodulators – Targeted Immunomodulators
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
 - c. Cardiovascular Agents – Antihypertensive Agents – Beta-Blockers
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups

4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- d. Cardiovascular Agents – Antilipemics – HMG-CoA Reductase Inhibitors (Statins)
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- e. Hematological Agents – Erythropoiesis-Stimulating Agents
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- f. Neurological Agents – Alzheimer’s Agents
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- g. Neurological Agents – Anti-Migraine Agents – Serotonin-Receptor Agonists
1. Public Comment

2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- h. Ophthalmic Agents – Ophthalmic Anti-infective/Anti-inflammatory Combinations
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- i. Otic Agents – Otic Anti-infectives – Otic Quinolones
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
6. **Annual Review – Established Drug Classes**
- a. Anti-infective Agents – Antivirals – Anti-Herpetic Agents
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP

5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- b. Anti-infective Agents – Antivirals – Influenza Agents
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- c. Anti-infective Agents – Quinolones – Quinolones – 3rd Generation
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- d. Cardiovascular Agents – Antihypertensive Agents – Vasodilators – Oral
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- e. Dermatological Agents – Antipsoriatic Agents – Topical Vitamin D Analogs
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action

- a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- f. Dermatological Agents – Topical Anti-infectives – Topical Antifungals (onychomycosis)
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- g. Electrolytic and Renal Agents – Phosphate Binding Agents
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- h. Genitourinary Agents – Benign Prostatic Hyperplasia (BPH) Agents – 5-Alpha Reductase Inhibitors
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- i. Hematological Agents – Anticoagulants – Injectable
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- j. Hematological Agents – Anticoagulants – Oral
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- k. Hormones and Hormone Modifiers – Antidiabetic Agents – Alpha-Glucosidase Inhibitors/Amylin analogs/Misc.
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- l. Hormones and Hormone Modifiers – Antidiabetic Agents – Incretin Mimetics
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups

4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- m. Musculoskeletal Agents – Bone Resorption Inhibitors – Bisphosphonates
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- n. Musculoskeletal Agents – Bone Resorption Inhibitors – Nasal Calcitonins
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- o. Ophthalmic Agents – Ophthalmic Antihistamines
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- p. Ophthalmic Agents – Ophthalmic Anti-infectives – Ophthalmic Macrolides
1. Public Comment

2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- q. Ophthalmic Agents – Ophthalmics for Dry Eye Disease
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

7. Annual Review – Drug Classes Without Proposed Changes

- a. Public Comment
- b. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP Without Changes
 1. Analgesics - Analgesic/Miscellaneous - Neuropathic Pain/Fibromyalgia Agents
 2. Analgesics - Analgesic/Miscellaneous - Tramadol and Related Drugs
 3. Analgesics - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Oral
 4. Analgesics - Opiate Agonists
 5. Analgesics - Opiate Agonists - Abuse Deterrent
 6. Anti-infective Agents - Aminoglycosides - Inhaled Aminoglycosides
 7. Anti-infective Agents - Antivirals - Alpha Interferons
 8. Anti-infective Agents - Antivirals - Anti-Hepatitis Agents - Polymerase Inhibitors/Combination Products
 9. Anti-infective Agents - Antivirals - Anti-Hepatitis Agents - Ribavirins
 10. Anti-infective Agents - Cephalosporins - Second-Generation Cephalosporins
 11. Anti-infective Agents - Cephalosporins - Third-Generation Cephalosporins
 12. Anti-infective Agents - Macrolides
 13. Anti-infective Agents - Quinolones - Quinolones - 2nd Generation
 14. Autonomic Agents - Sympathomimetics - Self-Injectable Epinephrine
 15. Biologic Response Modifiers - Multiple Sclerosis Agents - Injectable
 16. Biologic Response Modifiers - Multiple Sclerosis Agents - Oral
 17. Biologic Response Modifiers - Multiple Sclerosis Agents - Specific Symptomatic Treatment

18. Cardiovascular Agents - Antihypertensive Agents - Angiotensin II Receptor Antagonists
19. Cardiovascular Agents - Antihypertensive Agents - Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
20. Cardiovascular Agents - Antihypertensive Agents - Calcium-Channel Blockers
21. Cardiovascular Agents - Antihypertensive Agents - Direct Renin Inhibitors
22. Cardiovascular Agents - Antihypertensive Agents - Vasodilators - Inhaled
23. Cardiovascular Agents - Antilipemics - Bile Acid Sequestrants
24. Cardiovascular Agents - Antilipemics - Cholesterol Absorption Inhibitors
25. Cardiovascular Agents - Antilipemics - Fibric Acid Derivatives
26. Cardiovascular Agents - Antilipemics - Niacin Agents
27. Cardiovascular Agents - Antilipemics - Omega-3 Fatty Acids
28. Dermatological Agents - Topical Anti-infectives - Acne Agents: Topical, Benzoyl Peroxide, Antibiotics and Combination Products
29. Dermatological Agents - Topical Anti-infectives - Impetigo Agents: Topical
30. Dermatological Agents - Topical Anti-infectives - Topical Antivirals
31. Dermatological Agents - Topical Anti-infectives - Topical Scabicides
32. Dermatological Agents - Topical Anti-inflammatory Agents - Immunomodulators: Topical
33. Dermatological Agents - Topical Antineoplastics - Topical Retinoids
34. Gastrointestinal Agents - Antiemetics - Miscellaneous
35. Gastrointestinal Agents - Antiemetics - Serotonin-receptor antagonists/Combo
36. Gastrointestinal Agents - Antiulcer Agents - H2 blockers
37. Gastrointestinal Agents - Antiulcer Agents - Proton Pump Inhibitors (PPIs)
38. Gastrointestinal Agents - Functional Gastrointestinal Disorder Drugs
39. Gastrointestinal Agents - Gastrointestinal Anti-inflammatory Agents
40. Gastrointestinal Agents - Gastrointestinal Enzymes
41. Genitourinary Agents - Benign Prostatic Hyperplasia (BPH) Agents - Alpha-Blockers
42. Genitourinary Agents - Bladder Antispasmodics
43. Hematological Agents - Platelet Inhibitors
44. Hormones and Hormone Modifiers - Androgens
45. Hormones and Hormone Modifiers - Antidiabetic Agents - Biguanides
46. Hormones and Hormone Modifiers - Antidiabetic Agents - Dipeptidyl Peptidase-4 Inhibitors
47. Hormones and Hormone Modifiers - Antidiabetic Agents - Insulins (Vials, Pens and Inhaled)
48. Hormones and Hormone Modifiers - Antidiabetic Agents - Meglitinides
49. Hormones and Hormone Modifiers - Antidiabetic Agents - Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors
50. Hormones and Hormone Modifiers - Antidiabetic Agents - Sulfonylureas
51. Hormones and Hormone Modifiers - Antidiabetic Agents - Thiazolidinediones
52. Hormones and Hormone Modifiers - Pituitary Hormones - Growth hormone modifiers
53. Hormones and Hormone Modifiers - Progestins for Cachexia
54. Musculoskeletal Agents - Antigout Agents
55. Musculoskeletal Agents - Restless Leg Syndrome Agents
56. Musculoskeletal Agents - Skeletal Muscle Relaxants

57. Neurological Agents - Anticonvulsants - Barbiturates
58. Neurological Agents - Anticonvulsants - Benzodiazepines
59. Neurological Agents - Anticonvulsants - Hydantoins
60. Neurological Agents - Antiparkinsonian Agents - Non-ergot Dopamine Agonists
61. Ophthalmic Agents - Antiglaucoma Agents - Carbonic Anhydrase Inhibitors/Beta-Blockers
62. Ophthalmic Agents - Antiglaucoma Agents - Ophthalmic Prostaglandins
63. Ophthalmic Agents - Ophthalmic Anti-infectives - Ophthalmic Quinolones
64. Ophthalmic Agents - Ophthalmic Anti-inflammatory Agents - Ophthalmic Corticosteroids
65. Ophthalmic Agents - Ophthalmic Anti-inflammatory Agents - Ophthalmic Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
66. Psychotropic Agents - ADHD Agents
67. Psychotropic Agents - Antidepressants - Other
68. Psychotropic Agents - Antidepressants - Selective Serotonin Reuptake Inhibitors (SSRIs)
69. Psychotropic Agents - Antipsychotics - Atypical Antipsychotics - Oral
70. Psychotropic Agents - Anxiolytics, Sedatives, and Hypnotics
71. Psychotropic Agents - Psychostimulants - Narcolepsy Agents
72. Respiratory Agents - Nasal Antihistamines
73. Respiratory Agents - Respiratory Anti-inflammatory Agents - Leukotriene Receptor Antagonists
74. Respiratory Agents - Respiratory Anti-inflammatory Agents - Nasal Corticosteroids
75. Respiratory Agents - Respiratory Anti-inflammatory Agents - Phosphodiesterase Type 4 Inhibitors
76. Toxicology Agents - Antidotes - Opiate Antagonists
77. Toxicology Agents - Substance Abuse Agents - Mixed Opioid Agonists/Antagonists

- c. **For Possible Action:** Committee Discussion and Approval of the Drug Classes without Changes

8. Report by OptumRx on New Drugs to Market, New Generic Drugs to Market, and New Line Extensions

9. Closing Discussion

- a. Public comments on any subject
- b. Date and location of the next meeting
- c. Adjournment

PLEASE NOTE: Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to five minutes.

This notice and agenda have been posted at <http://dhcfp.nv.gov/> and notice.nv.gov/.

Notice of this meeting and draft copies of the changes will be available on or after the date of this notice at the DHCFP Web site <http://dhcfp.nv.gov/>, Carson City Central office and Las Vegas DHCFP. The agenda posting of this meeting can be viewed at the following locations: Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a draft copy of the changes will be mailed to you. Requests and/or written comments on the proposed changes may be sent to the Wendy Montgomery at the Division of Health Care Financing and Policy, 1100 E. William Street, Suite 101, Carson City, NV 89701.

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.

We are pleased to make accommodations for members of the public who have disabilities and wish to attend the meeting. If special arrangements are necessary, notify the Division of Health Care Financing and Policy as soon as possible and at least ten days in advance of the meeting, by e-mail at: wmontgomery@dhcfp.nv.gov, in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Wendy Montgomery at (775) 684-3722.
